sarcosine has been researched along with Chronic Disease in 6 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarcosine, glycine transporter inhibitor, increases glycine levels around NMDA receptor, improving primary negative symptoms of schizophrenia." | 9.27 | Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). ( Strzelecki, D; Urban-Kowalczyk, M; Wysokiński, A, 2018) |
| "Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia." | 9.14 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. ( Chang, YC; Huang, YJ; Lane, HY; Liao, CH; Lin, CH; Tsai, GE, 2010) |
| "Sarcosine, glycine transporter inhibitor, increases glycine levels around NMDA receptor, improving primary negative symptoms of schizophrenia." | 5.27 | Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). ( Strzelecki, D; Urban-Kowalczyk, M; Wysokiński, A, 2018) |
| "Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia." | 5.14 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. ( Chang, YC; Huang, YJ; Lane, HY; Liao, CH; Lin, CH; Tsai, GE, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strzelecki, D | 1 |
| Urban-Kowalczyk, M | 1 |
| Wysokiński, A | 1 |
| Lin, CY | 1 |
| Liang, SY | 1 |
| Chang, YC | 2 |
| Ting, SY | 1 |
| Kao, CL | 1 |
| Wu, YH | 1 |
| Tsai, GE | 2 |
| Lane, HY | 2 |
| Lin, CH | 1 |
| Huang, YJ | 1 |
| Liao, CH | 1 |
| Eussen, SJ | 1 |
| Nilsen, RM | 1 |
| Midttun, Ø | 1 |
| Hustad, S | 1 |
| IJssennagger, N | 1 |
| Meyer, K | 1 |
| Fredriksen, Å | 1 |
| Ulvik, A | 1 |
| Ueland, PM | 1 |
| Brennan, P | 1 |
| Johansson, M | 1 |
| Bueno-de-Mesquita, B | 1 |
| Vineis, P | 1 |
| Chuang, SC | 1 |
| Boutron-Ruault, MC | 1 |
| Dossus, L | 1 |
| Perquier, F | 1 |
| Overvad, K | 1 |
| Teucher, B | 1 |
| Grote, VA | 1 |
| Trichopoulou, A | 1 |
| Adarakis, G | 1 |
| Plada, M | 1 |
| Sieri, S | 1 |
| Tumino, R | 1 |
| de Magistris, MS | 1 |
| Ros, MM | 1 |
| Peeters, PH | 1 |
| Redondo, ML | 1 |
| Zamora-Ros, R | 1 |
| Chirlaque, MD | 1 |
| Ardanaz, E | 1 |
| Sonestedt, E | 1 |
| Ericson, U | 1 |
| Schneede, J | 1 |
| van Guelpen, B | 1 |
| Wark, PA | 1 |
| Gallo, V | 1 |
| Norat, T | 1 |
| Riboli, E | 1 |
| Vollset, SE | 1 |
| Binzak, BA | 1 |
| Wevers, RA | 1 |
| Moolenaar, SH | 1 |
| Lee, YM | 1 |
| Hwu, WL | 1 |
| Poggi-Bach, J | 1 |
| Engelke, UF | 1 |
| Hoard, HM | 1 |
| Vockley, JG | 1 |
| Vockley, J | 1 |
| Johnson, JA | 1 |
| Davis, JO | 1 |
| Spielman, WS | 1 |
| Freeman, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine[NCT00491569] | Phase 2 | 60 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for sarcosine and Chronic Disease
| Article | Year |
|---|---|
Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study).
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combina | 2018 |
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzoates; Chronic Disease; Cognition; D-Amino- | 2017 |
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug | 2010 |
3 other studies available for sarcosine and Chronic Disease
| Article | Year |
|---|---|
North-south gradients in plasma concentrations of B-vitamins and other components of one-carbon metabolism in Western Europe: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.
Topics: Adult; Aged; Alcohol Drinking; Chronic Disease; Ethnicity; Europe; Female; Folic Acid; Glycine; Heal | 2013 |
Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Base Sequence; Black People; Blotting, Western; | 2001 |
The role of the renin--angiotensin system in experimental renal hypertension in dogs.
Topics: Alanine; Angiotensin II; Animals; Blood Pressure; Blood Urea Nitrogen; Body Temperature; Chronic Dis | 1974 |